These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside. Lizardo DY; Kuang C; Hao S; Yu J; Huang Y; Zhang L Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188447. PubMed ID: 33035640 [TBL] [Abstract][Full Text] [Related]
6. Expanding the Scope of Immunotherapy in Colorectal Cancer: Current Clinical Approaches and Future Directions. Kreidieh M; Mukherji D; Temraz S; Shamseddine A Biomed Res Int; 2020; 2020():9037217. PubMed ID: 32090113 [TBL] [Abstract][Full Text] [Related]
7. Potent therapeutic strategy in gastric cancer with microsatellite instability-high and/or deficient mismatch repair. Ooki A; Osumi H; Yoshino K; Yamaguchi K Gastric Cancer; 2024 Sep; 27(5):907-931. PubMed ID: 38922524 [TBL] [Abstract][Full Text] [Related]
8. Improving the efficiency of immune checkpoint inhibitors for metastatic pMMR/MSS colorectal cancer: Options and strategies. Yang C; Zhao L; Lin Y; Wang S; Ye Y; Shen Z Crit Rev Oncol Hematol; 2024 Aug; 200():104204. PubMed ID: 37984588 [TBL] [Abstract][Full Text] [Related]
9. Immunotherapy in Metastatic Colorectal Cancer: Could the Latest Developments Hold the Key to Improving Patient Survival? Damilakis E; Mavroudis D; Sfakianaki M; Souglakos J Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32268531 [TBL] [Abstract][Full Text] [Related]
10. BRAF + EGFR +/- MEK inhibitors after immune checkpoint inhibitors in BRAF V600E mutated and deficient mismatch repair or microsatellite instability high metastatic colorectal cancer. Ambrosini M; Tougeron D; Modest D; Guimbaud R; Kopetz S; Decraecker M; Kim S; Coutzac C; Perkins G; Alouani E; Marmorino F; Pernot S; Sinicrope FA; Elez E; Parent P; Cremolini C; Pietrantonio F; Lonardi S; Gallois C; Taieb J Eur J Cancer; 2024 Oct; 210():114290. PubMed ID: 39216175 [TBL] [Abstract][Full Text] [Related]
11. Impact of mismatch repair or microsatellite status on the prognosis and efficacy to chemotherapy in metastatic colorectal cancer patients: A bi-institutional, propensity score-matched study. Yao YC; Jin Y; Lei XF; Wang ZX; Zhang DS; Wang FH; Li YH; Xu RH; Wang F J Cancer; 2022; 13(9):2912-2921. PubMed ID: 35912009 [No Abstract] [Full Text] [Related]
12. Immunocheckpoint Inhibitors in Microsatellite-Stable or Proficient Mismatch Repair Metastatic Colorectal Cancer: Are We Entering a New Era? Matteucci L; Bittoni A; Gallo G; Ridolfi L; Passardi A Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958363 [TBL] [Abstract][Full Text] [Related]
13. Latest evidence on immune checkpoint inhibitors in metastatic colorectal cancer: A 2022 update. Boukouris AE; Theochari M; Stefanou D; Papalambros A; Felekouras E; Gogas H; Ziogas DC Crit Rev Oncol Hematol; 2022 May; 173():103663. PubMed ID: 35351582 [TBL] [Abstract][Full Text] [Related]
14. A subset of patients with MSS/MSI-low-colorectal cancer showed increased CD8(+) TILs together with up-regulated IFN-γ. Kikuchi T; Mimura K; Okayama H; Nakayama Y; Saito K; Yamada L; Endo E; Sakamoto W; Fujita S; Endo H; Saito M; Momma T; Saze Z; Ohki S; Kono K Oncol Lett; 2019 Dec; 18(6):5977-5985. PubMed ID: 31788072 [TBL] [Abstract][Full Text] [Related]
15. Current Landscape and Potential Challenges of Immune Checkpoint Inhibitors in Microsatellite Stable Metastatic Colorectal Carcinoma. San-Román-Gil M; Torres-Jiménez J; Pozas J; Esteban-Villarrubia J; Albarrán-Fernández V; Álvarez-Ballesteros P; Chamorro-Pérez J; Rosero-Rodríguez D; Orejana-Martín I; Martínez-Delfrade Í; Reguera-Puertas P; Fuentes-Mateos R; Ferreiro-Monteagudo R Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765821 [TBL] [Abstract][Full Text] [Related]
16. The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy. Toh JWT; de Souza P; Lim SH; Singh P; Chua W; Ng W; Spring KJ Clin Colorectal Cancer; 2016 Dec; 15(4):285-291. PubMed ID: 27553906 [TBL] [Abstract][Full Text] [Related]
17. Recent Advances in the Clinical Development of Immune Checkpoint Blockade Therapy for Mismatch Repair Proficient (pMMR)/non-MSI-H Metastatic Colorectal Cancer. Lee JJ; Chu E Clin Colorectal Cancer; 2018 Dec; 17(4):258-273. PubMed ID: 30072278 [TBL] [Abstract][Full Text] [Related]
18. Tumour mutational burden as a biomarker in patients with mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint inhibitors. Manca P; Corti F; Intini R; Mazzoli G; Miceli R; Germani MM; Bergamo F; Ambrosini M; Cristarella E; Cerantola R; Boccaccio C; Ricagno G; Ghelardi F; Randon G; Leoncini G; Milione M; Fassan M; Cremolini C; Lonardi S; Pietrantonio F Eur J Cancer; 2023 Jul; 187():15-24. PubMed ID: 37099945 [TBL] [Abstract][Full Text] [Related]